The Technical Analyst
Leap Therapeutics Inc [LPTX]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Leap Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.00% $1.160
Last updated: 8 aug 2022 - 0:36
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 102.45 mill |
| EPS: | -0.440 |
| P/E: | 0.000 |
| Earnings Date: | Aug 11, 2022 |
| SharesOutstanding: | 88.32 mill |
| Avg Daily Volume: | 0.705 mill |
| RATING 2022-08-05 |
|---|
| B+ |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.50 (115.43%) $1.339 |
| Date: 2022-08-08 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.079 - 1.241 ( +/- 6.98%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-01-31 | Cavanaugh James H | Buy | 55 000 | Stock Option (Right to Buy) |
| 2022-01-31 | O'mahony John Mark | Buy | 225 000 | Restricted Stock Units |
| 2022-01-31 | Mashiach Nissim | Buy | 55 000 | Stock Option (Right to Buy) |
| 2022-01-31 | Li William | Buy | 55 000 | Stock Option (Right to Buy) |
| 2022-01-31 | Lawlor Augustine | Buy | 225 000 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 47.28 |
| Last 100 transactions |
| Buy: 18 499 912 | Sell: 4 904 118 |
Forecast:
16:00 - $1.160
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $1.160
Forecast 2: 16:00 - $1.160
Forecast 3: 16:00 - $1.160
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.160 (0.00% ) |
| Volume | 0.602 mill |
| Avg. Vol. | 0.705 mill |
| % of Avg. Vol | 85.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LPTX
68 Signals | Accuracy: 10.29% | Accuracy Buy: 14.71% | Accuracy Sell: 5.88%
Avg return buy: -0.39 % | Avg return sell: 0.69 %
$1 invested is now $0.87 or -12.61% since 25-07-22
| Date | Signal | @ | Closed | % | Aug 5 - 13:09 | sell | $1.181 | N/A | Active |
|---|---|---|---|---|
| Aug 5 - 12:11 | buy | $1.190 | $1.181 @ Aug 5 - 13:09 | -0.76% |
| Aug 5 - 12:03 | sell | $1.163 | $1.190 @ Aug 5 - 12:11 | 2.32% |
| Aug 5 - 11:48 | buy | $1.170 | $1.163 @ Aug 5 - 12:03 | -0.60% |
| Aug 5 - 11:15 | sell | $1.170 | $1.170 @ Aug 5 - 11:48 | 0.00% |
| Aug 5 - 10:55 | buy | $1.180 | $1.170 @ Aug 5 - 11:15 | -0.85% |
| Aug 5 - 10:42 | sell | $1.160 | $1.180 @ Aug 5 - 10:55 | 1.72% |
| Aug 5 - 10:22 | buy | $1.175 | $1.160 @ Aug 5 - 10:42 | -1.28% |
| Aug 5 - 09:42 | sell | $1.170 | $1.175 @ Aug 5 - 10:22 | 0.43% |
| Aug 5 - 09:31 | buy | $1.180 | $1.170 @ Aug 5 - 09:42 | -0.85% |
LPTX
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 23 full-time employees. The Company’s programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and spread and specific mechanisms that activate the body’s immune system to identify and attack cancer. DKN-01 and TRX518 are its clinical stage programs. DKN-01 is a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). GITR is a receptor found on the surface of a wide range of immune cells.
Latest Press Releases
2022-07-12 07:00:00 - Press Release
Leap Therapeutics Announces Initiation Of New Dkn-01 Clinical Trials In Gastric Cancer, Colorectal Cancer And Endometrial Cancer
Randomized controlled first-line gastric cancer trial of dkn-01 plus tislelizumab and chemotherapy in collaboration with beigene leap to host r&d day today at 12:00 p.m. et cambridge, mass.
2022-06-27 07:00:00 - Press Release
Leap Therapeutics To Host Virtual R&d Day On July 12, 2022
Cambridge, mass. , june 27, 2022 /prnewswire/ -- leap therapeutics, inc. (nasdaq: lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a virtual r&d day on july 12, 2022 at 12:00 pm et.
2022-05-13 07:00:00 - Press Release
Leap Therapeutics Reports First Quarter 2022 Financial Results
Cambridge, mass. , may 13, 2022 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter ended march 31, 2022.
2022-03-11 07:00:00 - Press Release
Leap Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results
Cambridge, mass., march 11, 2022 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended december 31, 2021.
2021-11-12 07:00:00 - Press Release
Leap Therapeutics Reports Third Quarter 2021 Financial Results
Cambridge, mass., nov. 12, 2021 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the third quarter ended september 30, 2021.
Latest News
2022-07-08 09:20:17 - Zacks Investment Research
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).
2022-06-27 14:58:18 - Seeking Alpha
Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022
Positive results using DKN-01 plus chemotherapy for the treatment of patients with metastatic castration-resistant prostate cancer were presented at ASCO 2022 medical conference. The global prostate cancer market could reach $12 billion by 2025.
2022-04-19 17:08:16 - PennyStocks
Check These 3 Penny Stocks Out For Your Watchlist Right in Late-April
Check these three penny stocks out for your watchlist right now The post Check These 3 Penny Stocks Out For Your Watchlist Right in Late-April appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-24 07:00:00 - PRNewsWire
Leap Therapeutics to Present at B. Riley Securities Oncology Investor Conference
CAMBRIDGE, Mass., Jan. 24, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E.
2022-01-19 14:07:27 - The Motley Fool
Why Leap Therapeutics Stock Is Surging Today
2022-01-19 06:07:06 - Benzinga
Leap Therapeutics Says DKN-01 Combo Regime Show Compelling Efficacy In Gastric Cancer Patients
Leap Therapeutics Inc (NASDAQ: LPTX) will present updated data from the DisTinGuish Phase 2a study of DKN-01, in combination with tislelizumab in gastric or gastric gastroesophageal junction cancer (G/GEJ). Data will be shared at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
2022-01-18 17:00:00 - PRNewsWire
Leap Therapeutics to Present Positive New Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ASCO GI Cancers Symposium
CAMBRIDGE, Mass., Jan. 18, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company will be presenting updated data from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene's anti-PD-1 antibody, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium being held on January 20-22, 2022.
2022-01-16 10:30:00 - The Motley Fool
2 Risky Growth Stocks That Could Make You Filthy Rich
2022-01-11 12:11:58 - PennyStocks
7 Short Squeeze Penny Stocks To Buy For Under $5 Right Now
Short squeeze penny stocks to watch right now. The post 7 Short Squeeze Penny Stocks To Buy For Under $5 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-12-31 15:04:44 - PennyStocks
Top Penny Stocks To Buy According To Analysts & Targets Up To 615%
Penny stocks with hight hopes from analysts. The post Top Penny Stocks To Buy According To Analysts & Targets Up To 615% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.